次世代がん診断薬市場：技術、がんタイプ、用途、機能別-2023-2030年の世界予測

次世代がん診断薬の世界市場は大きく成長し、2023年には97億7,115万米ドル、CAGR 23.93%と予測され、2030年には443億6,332万米ドルに達すると予測されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界の次世代がん診断薬市場を評価するために不可欠です。事業戦略や製品満足度などの主要指標を検証することで、ベンダーの包括的な評価を提供し、ユーザーが特定のニーズに基づいて情報に基づいた意思決定を行えるようにします。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展：有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化：新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向：COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション：将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします：

1.次世代がん診断薬の世界市場規模および予測は？

2.予測期間中、世界の次世代がん診断薬市場を形成するCOVID-19の阻害要因と影響は？

3.次世代がん診断薬の世界市場において予測期間中に投資すべき製品/セグメント/アプリケーション/分野は？

4.次世代がん診断薬の世界市場における競争戦略は？

5.次世代がん診断薬の世界市場における技術動向と規制の枠組みは？

6.次世代がん診断薬の世界市場における主要ベンダーの市場シェアは？

7.次世代がん診断薬の世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界的に増加するがん症例の負担と効率的な診断の必要性
    • がん管理におけるマイクロ流体チップの利用が拡大
    • がん検診に対する政府の取り組み
  • 抑制要因
    • 多額の投資と診断の不十分な標準化
  • 機会
    • 個別化された高度なゲノム医療の普及
    • 次世代がん診断薬の技術の進歩
  • 課題
    • NGC診断に関連する制限とリスク
• 市場動向
• COVID-19の累積的な影響
• ロシア・ウクライナ紛争の累積的影響
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制の枠組み
• 顧客のカスタマイズ

第6章 次世代がん診断薬市場：技術別

• クラスター化された規則的な間隔の短い回文繰り返しの診断
• DNAマイクロアレイ
• ラボオンチップ &逆転写PCR
• 分子診断学
• 次世代シーケンス
• タンパク質マイクロアレイ
• qPCRと多重化

第7章 次世代がん診断薬市場がんの種類別

• 膀胱がん
• 乳がん
• 子宮頸がん
• 結腸直腸がん
• 腎臓がん
• 肺がん
• 膵臓がん
• 前立腺がん
• 甲状腺がん
• 子宮がん

第8章 次世代がん診断薬市場：用途別

• がん検診
• コンパニオン診断
• 予後
• リスク分析
• 治療モニタリング

第9章 次世代がん診断薬市場：機能別

• バイオマーカーの開発
• CTC分析
• エピジェネティック解析
• 遺伝子解析
• プロテオーム解析

第10章 南北アメリカの次世代がん診断薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の次世代がん診断薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの次世代がん診断薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• FPNVポジショニングマトリクス
• 市場シェア分析：主要企業別
• 競合シナリオ分析：主要企業別

第14章 掲載企業一覧

第15章 付録

• ディスカッションガイド
• ライセンスと価格について

LIST OF FIGURES

• FIGURE 1. NEXT-GENERATION CANCER DIAGNOSTICS MARKET RESEARCH PROCESS
• FIGURE 2. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2022 VS 2030
• FIGURE 3. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2022 VS 2030 (%)
• FIGURE 5. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2022 VS 2030 (%)
• FIGURE 6. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)
• FIGURE 7. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2022 VS 2030 (%)
• FIGURE 8. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 9. NEXT-GENERATION CANCER DIAGNOSTICS MARKET DYNAMICS
• FIGURE 10. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 15. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 18. NEXT-GENERATION CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 19. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 5. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY DNA MICROARRAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LAB-ON-A-CHIP & REVERSE TRANSCRIPTASE-PCR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MICROARRAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY QPCR & MULTIPLEXING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 13. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY THYROID CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY UTERINE CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 24. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER SCREENING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RISK ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 30. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CTC ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEOMIC ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 40. ARGENTINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 42. ARGENTINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 43. ARGENTINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 44. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 45. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 46. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 47. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 48. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 49. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 50. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 51. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 53. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 54. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 55. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 59. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 60. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 65. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 66. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 68. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 69. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 70. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 71. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 72. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 73. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 74. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 75. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 76. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 77. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 78. INDONESIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 79. INDONESIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 80. INDONESIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 81. INDONESIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 82. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 83. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 84. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 85. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 86. MALAYSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 87. MALAYSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 88. MALAYSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 89. MALAYSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 90. PHILIPPINES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 91. PHILIPPINES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 92. PHILIPPINES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 93. PHILIPPINES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 94. SINGAPORE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 95. SINGAPORE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 96. SINGAPORE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 97. SINGAPORE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 98. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 99. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 100. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 101. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 102. TAIWAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 103. TAIWAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 104. TAIWAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 105. TAIWAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 106. THAILAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 107. THAILAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 108. THAILAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 109. THAILAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 110. VIETNAM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 111. VIETNAM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 112. VIETNAM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 113. VIETNAM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 114. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 115. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 116. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 117. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 118. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 119. DENMARK NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 120. DENMARK NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 121. DENMARK NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 122. DENMARK NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 123. EGYPT NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 124. EGYPT NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 125. EGYPT NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 126. EGYPT NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 127. FINLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 128. FINLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 129. FINLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 130. FINLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 131. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 132. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 133. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 134. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 135. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 136. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 137. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 138. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 139. ISRAEL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 140. ISRAEL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 141. ISRAEL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 142. ISRAEL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 143. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 144. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 145. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 146. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 147. NETHERLANDS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 148. NETHERLANDS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 149. NETHERLANDS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 150. NETHERLANDS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 151. NIGERIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 152. NIGERIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 153. NIGERIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 154. NIGERIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 155. NORWAY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 156. NORWAY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 157. NORWAY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 158. NORWAY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 159. POLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 160. POLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 161. POLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 162. POLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 163. QATAR NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 164. QATAR NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 165. QATAR NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 166. QATAR NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 167. RUSSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 168. RUSSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 169. RUSSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 170. RUSSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 171. SAUDI ARABIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 172. SAUDI ARABIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 173. SAUDI ARABIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 174. SAUDI ARABIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 175. SOUTH AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 176. SOUTH AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 177. SOUTH AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 178. SOUTH AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 179. SPAIN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 180. SPAIN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 181. SPAIN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 182. SPAIN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 183. SWEDEN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 184. SWEDEN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 185. SWEDEN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 186. SWEDEN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 187. SWITZERLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 188. SWITZERLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 189. SWITZERLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 190. SWITZERLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 191. TURKEY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 192. TURKEY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 193. TURKEY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 194. TURKEY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 195. UNITED ARAB EMIRATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 196. UNITED ARAB EMIRATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 197. UNITED ARAB EMIRATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 198. UNITED ARAB EMIRATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 199. UNITED KINGDOM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 200. UNITED KINGDOM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 201. UNITED KINGDOM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 202. UNITED KINGDOM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 203. NEXT-GENERATION CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 204. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 205. NEXT-GENERATION CANCER DIAGNOSTICS MARKET LICENSE & PRICING

The Global Next-Generation Cancer Diagnostics Market is forecasted to grow significantly, with a projected USD 9,771.15 million in 2023 at a CAGR of 23.93% and expected to reach a staggering USD 44,363.32 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Next-Generation Cancer Diagnostics Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Next-Generation Cancer Diagnostics Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Technology, market is studied across Clustered Regularly Interspaced Short Palindromic Repeats Diagnostics, DNA Microarrays, Lab-on-a-Chip & Reverse Transcriptase-PCR, Molecular Diagnostics, Next Generation Sequencing, Protein Microarrays, and qPCR & Multiplexing. The Next Generation Sequencing commanded largest market share of 23.96% in 2022, followed by qPCR & Multiplexing.

Based on Cancer Type, market is studied across Bladder Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Kidney Cancer, Lung Cancer, Pancreatic Cancer, Prostate Cancer, Thyroid Cancer, and Uterine Cancer. The Lung Cancer commanded largest market share of 17.33% in 2022, followed by Colorectal Cancer.

Based on Application, market is studied across Cancer Screening, Companion Diagnostics, Prognostics, Risk Analysis, and Therapeutic Monitoring. The Cancer Screening commanded largest market share of 23.14% in 2022, followed by Companion Diagnostics.

Based on Function, market is studied across Biomarker Development, CTC Analysis, Epigenetic Analysis, Genetic Analysis, and Proteomic Analysis. The Biomarker Development commanded largest market share of 31.96% in 2022, followed by CTC Analysis.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 39.07% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Next-Generation Cancer Diagnostics Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Next-Generation Cancer Diagnostics Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Next-Generation Cancer Diagnostics Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Next-Generation Cancer Diagnostics Market?

4. What is the competitive strategic window for opportunities in the Global Next-Generation Cancer Diagnostics Market?

5. What are the technology trends and regulatory frameworks in the Global Next-Generation Cancer Diagnostics Market?

6. What is the market share of the leading vendors in the Global Next-Generation Cancer Diagnostics Market?

7. What modes and strategic moves are considered suitable for entering the Global Next-Generation Cancer Diagnostics Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Next-Generation Cancer Diagnostics Market, by Technology, 2022 vs 2030
• 4.3. Next-Generation Cancer Diagnostics Market, by Cancer Type, 2022 vs 2030
• 4.4. Next-Generation Cancer Diagnostics Market, by Application, 2022 vs 2030
• 4.5. Next-Generation Cancer Diagnostics Market, by Function, 2022 vs 2030
• 4.6. Next-Generation Cancer Diagnostics Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing Burden of Cancer Cases Globally and Need for Efficient Diagnostics
    • 5.1.1.2. Growing Utilization of Microfluidic Chips in Cancer Management
    • 5.1.1.3. Government Initiatives Towards Cancer Screening
  • 5.1.2. Restraints
    • 5.1.2.1. High Investment and Insufficient Standardization of Diagnostics
  • 5.1.3. Opportunities
    • 5.1.3.1. Proliferation of Personalized and Advanced Genome Medicine
    • 5.1.3.2. Technological Advancements in Next-Generation Cancer Diagnostics
  • 5.1.4. Challenges
    • 5.1.4.1. Limitations and Risks Associated with NGC Diagnostics
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Next-Generation Cancer Diagnostics Market, by Technology

• 6.1. Introduction
• 6.2. Clustered Regularly Interspaced Short Palindromic Repeats Diagnostics
• 6.3. DNA Microarrays
• 6.4. Lab-on-a-Chip & Reverse Transcriptase-PCR
• 6.5. Molecular Diagnostics
• 6.6. Next Generation Sequencing
• 6.7. Protein Microarrays
• 6.8. qPCR & Multiplexing

7. Next-Generation Cancer Diagnostics Market, by Cancer Type

• 7.1. Introduction
• 7.2. Bladder Cancer
• 7.3. Breast Cancer
• 7.4. Cervical Cancer
• 7.5. Colorectal Cancer
• 7.6. Kidney Cancer
• 7.7. Lung Cancer
• 7.8. Pancreatic Cancer
• 7.9. Prostate Cancer
• 7.10. Thyroid Cancer
• 7.11. Uterine Cancer

8. Next-Generation Cancer Diagnostics Market, by Application

• 8.1. Introduction
• 8.2. Cancer Screening
• 8.3. Companion Diagnostics
• 8.4. Prognostics
• 8.5. Risk Analysis
• 8.6. Therapeutic Monitoring

9. Next-Generation Cancer Diagnostics Market, by Function

• 9.1. Introduction
• 9.2. Biomarker Development
• 9.3. CTC Analysis
• 9.4. Epigenetic Analysis
• 9.5. Genetic Analysis
• 9.6. Proteomic Analysis

10. Americas Next-Generation Cancer Diagnostics Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Next-Generation Cancer Diagnostics Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Next-Generation Cancer Diagnostics Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. FPNV Positioning Matrix
• 13.2. Market Share Analysis, By Key Player
• 13.3. Competitive Scenario Analysis, By Key Player

14. List of Company Mentioned

15. Appendix

• 15.1. Discussion Guide
• 15.2. License & Pricing